Skip to main content

Advertisement

Table 1 Baseline demographic and clinical characteristics of TDF-treated HIV/HBV co-infected patients

From: HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons

   143 patients 128 patients
   Detectable HBV DNA Undetectable HBV DNA
Origin: Caucasian 121 (84 %) 88 (68 %)
  African 16 (11 %) 36 (28 %)
  Asian 10 (4 %) 4 (3 %)
Age in years (median) (range) 41 (23–73) 40 (21–75)
Sex M:F 122 (85 %):21 (15 %) 101 (79 %):27 (21 %)
CD4 count (median) (range) 295 (6–1143) 326 (21–1512)
HIV viremia (median) log10 cp/ml (range) 2.84 (0–6.08) 1.74 (0–6.01)
HIV treatment on HAART 82 (57 %) 84 (66 %)
  treatment naïve 31 (22 %) 15 (12 %)
  off HAART 30 (21 %) 29 (23 %)
Hepatitis delta infection positive 9 4
  negative 17 8
  missing data 117 116
HCV coinfection positive 31 37
  negative 110 87
  missing data 2 4
ALT (median) IU/ml (range) IU/ml 47 (11–1020) 32 (7–284)
AST (median) IU/ml (range) IU/ml 35 (19–375) 33 (14–135)
INR (median) (range) 1 (0.9-2.6) 1 (0.9-1.2)
Total Bilirubin (median) umol/L (range) 9 (4–243) 9 (2–30)
  (range) 39 (20–49) 39 (32–52)
  (range) 77 (37–214) 76 (41–150)